Genomic Health, Inc. (GHDX) - Product Pipeline Analysis, 2015 Update

Albany, NY -- (ReleaseWire) -- 05/06/2015 -- Genomic Health, Inc. (Genomic Health) is a provider of genomic-based clinical laboratory services for the treatment of cancer. The companys commercial product portfolio comprises Onco type DX breast cancer test, Onco type DX colon cancer test, and Onco type DX prostate cancer test. It conducts extensive research and development activities to optimize the treatment of urologic cancers including prostate, bladder, and kidney cancers, and additional treatment decisions in breast and colon cancers. Genomic Health develops these products using its Onco type DX platform, a technology which uses RT-PCR approach to improve cancer treatment decisions. The company operates along with its subsidiaries in over 30 countries including the UK, Germany, France, Ireland, Italy, Japan, the Netherlands, Canada, and the US. Genomic Health is headquartered in Redwood City, California, the US.The company strives to offer personalized care for the UK breast cancer patients. To this end, Genomic Health announced the availability of Onco type DX test to the eligible breast cancer patients through the National Health Service (NHS) in England effective April 01, 2015.